The Pharmaceutical Research in Immune and Microbiome Engineering Laboratory (PRIME Lab) develops microbiome-inspired therapeutic strategies for allergic, autoimmune, and inflammatory diseases. Our research draws inspiration from the metabolites and molecular signals produced by the gut microbiome that shape host immune responses and maintain immune homeostasis. Translating these signals into effective treatments remains challenging because of their complex biological interactions and limited control over tissue exposure. We address these challenges by integrating biomaterials, immunology, microbiome engineering, and quantitative pharmacology to engineer programmable therapeutic systems designed to precisely control where, when, and how immunoregulatory signals are delivered.
We engineer biomaterials and drug delivery systems to modulate immune responses at mucosal tissues, e.g., in the intestine and lung. Our goal is to promote immune tolerance, reduce chronic inflammation, and support epithelial barrier function through targeted and sustained delivery of immunoregulatory molecules. By studying interactions among delivery systems, epithelial cells, and immune cells, we seek to understand how the location and duration of exposure shape mucosal immune responses.
Current efforts include oral delivery platforms for intestinal inflammation and food allergy, as well as pulmonary delivery of microbial metabolites for allergic airway inflammation. We also explore bacterial vesicles as platforms for delivering antigens and promoting immune tolerance. These studies connect delivery design with investigations of epithelial and immune cell responses, with the goal of developing therapeutic strategies that address both immune dysregulation and barrier dysfunction.
We develop pharmaceutical approaches to harness microbial metabolites and other microbial signals as therapeutics. Our work includes polymeric prodrugs and nanoparticles designed to deliver short-chain fatty acids and tryptophan metabolites to intestinal and lymphoid tissues, as well as injectable formulations that sustain exposure over extended periods. We also engineer synthetic microbiome mimics that combine microbial components with biomaterials to investigate how defined microbial signals influence host responses.
A central focus is understanding how delivery determines biological activity. We combine experimental studies with physiologically based pharmacokinetic modeling to investigate how formulation properties, host physiology, and microbial activity influence drug release, tissue exposure, and therapeutic responses. This includes precise delivery to the distal gastrointestinal tract and the study of interactions among therapeutic compounds, the microbiome, and the host. By connecting these insights with delivery system design, we aim to develop more predictable and effective microbiome-inspired therapies for allergic, autoimmune, and inflammatory diseases.